News

News

Hear what the media is saying about Vistagen Therapeutics, and the products we are developing to exceed the current standard of care.

Media Coverage

Talking Biotech: Treating Mental Illness through Nasal Drug Delivery - Shawn Singh
Talking Biotech: Treating Mental Illness through Nasal Drug Delivery - Shawn Singh
Read
Bio Report logo
The Bio Report: A Rapid Onset Nasal Spray to Treat Mental Health Conditions
Read
The Biotech Project
The Biotech Project: Featuring Shawn Singh
Read

Press Releases

Long-term intranasal administration of fasedienol, used as-needed up to four times a day in daily life, was safe and well-tolerated in nearly 500 patients with social anxiety disorder (SAD) Patients self-administered over 30,000 doses of fasedienol in real-world settings , with a mean study
U.S. Phase 1 study with newly optimized formulation intended to facilitate Phase 2B development of itruvone as a stand-alone treatment of major depressive disorder Top line results anticipated in Q2 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 2, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that
PH80 patent portfolio now includes U.S. patents for treatment of both hot flashes and migraine SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 1, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living